Top Market Movers: GSKs Vaccine Success, Snowflakes Revenue Surge, and More!

1. Gsk Plc (NYSE: GSK)
Gsk Plc gained solidly by 5.84%. GlaxoSmithKline (GSK) reported that its RSV vaccine maintains protection for three quarters with a cumulative efficacy of 62.9% for older adults. GSK also reached settlements regarding Zantac lawsuits and had two RSV vaccine patents invalidated by Pfizer in a UK court.

2. Snowflake (NYSE: SNOW)
Snowflake gained solidly by 5.42%. Snowflake reported revenue of $16.98 billion for the period ending July 31, 2024, up 30.82% year-over-year. DA Davidson and Rosenblatt maintain a Buy rating with target prices of $175 and $180, respectively. Argus Research rates it Hold. Snowflake plans to raise $2 billion via bonds.

3. Atlassian (Nasdaq: TEAM)
Atlassian gained solidly by 5.4%. Atlassian disclosed multiple insider transactions in October 2024, involving major shareholders like Cannon-Brookes Michael and Farquhar Scott selling shares. Additionally, Raymond James upgraded Atlassian to Outperform with a $200 price target.

4. Royal Caribbean Cruises Ltd. (NYSE: RCL)
Royal Caribbean Cruises Ltd. gained solidly by 5.26%. Royal Caribbean Cruises received "Buy" ratings from Citigroup with a $253.00 target price, Truist Securities at $204.00, and was maintained as "Overweight" by JP Morgan at a $213.00 target price. Recent insider transactions involved executives selling shares.

5. Corning Incorporated (NYSE: GLW)
Corning Incorporated gained solidly by 4.82%. Corning's Q2 2024 revenue reached $62.26 billion, down 3.04% year-over-year, with a net profit of $3.47 billion. Deutsche Bank, B of A Securities, and Susquehanna maintained buy/positive ratings, setting price targets at $49, $51, and $55 respectively.